The facts speak for themselves…
Healthcare has the greatest growth potential of any industry in the coming decade.
Combine these three megatrends – a huge influx of new consumers… trillions of new dollars pouring into the industry… and a vast expansion of breakthrough medical technology… – and we’ll soon be amidst a lightning fast, continuous transformation of virtually every company in this $4-trillion market.
Indeed – a monumental “money shift” – creating the most potent investment situation of our lifetimes.
The only question is: Which companies are going to take the lion’s share of this $4-trillion?
Over the next few minutes, I’ll give you the full story on the very best ones… including the single company I believe will be by far the biggest profit producer of 2012.
But first, let me give you an idea just how much money could be made if this situation pays off as I believe it will…
It’s no secret investors can make extraordinary returns from medical breakthroughs.
The trick is knowing where – and when – to get in ahead of the crowd. Once you’re reading about a firm in The Wall Street Journal or on CNBC, the horse has most likely already left the barn.
But move in advance of the masses and you can see immense rewards.
Let’s say, on April 1, 2009 you had purchased shares of Dendreon, at the time a small cancer treatment company. Perhaps you had reason to believe they were about to announce favorable results on one of their clinical trials for prostate cancer.
You would have been sitting pretty as their stock shot from $4 to $22 in less than 4 weeks.
Or take a look at what happened to Generex Biotechnology, to see how medical breakthroughs can make informed early investors very wealthy… very quickly.
January brought good news to the company. A settled lawsuit… a multi-million-dollar private placement… But perhaps most importantly, on January 9, 2006, the company announced plans to undertake initial trials for an insulin spray for sufferers of type 1 diabetes.
The stock skyrocketed 293% in just over 2 months. You could have turned $10,000 into nearly $30,000.
And then there’s Human Genome Sciences. For months, their stock sold at around $2.50… when all hell broke loose. On July 20, 2009, they announced positive late-stage trial results of their experimental lupus treatment.
Now, just to illustrate a point, let’s go one step further…
Imagine if you invested $10,000 in Dendreon in April and cashed out your $55,000 later that same month. And let’s say you then reinvested that in Human Genome Sciences in July and cashed out in August.
From a grubstake of $10,000, you’d be sitting on nearly $250,000 – in just 4 months.
Of course, not every healthcare company shows results like these. And no one who plays the market has perfect timing with each and every move. I don’t believe that and I don’t expect you to, either.
But what if the investor had access to the right connections in the field… and access to immediate, authoritative analysis…
Someone with a track record of consistently targeting these types of fast-moving opportunities.
Today I am offering you a rare chance to gain these advantages… to, in effect, have an expert working on your side…